Summary
Plasma C-peptide and serum insulin antibody levels were determined in 5 diabetic patients undergoing vascularized pancreatic transplantation. The grafts functioned well at first and exogenous insulin could be withdrawn, but one to 7 weeks later the grafts were rejected. After the transplantation there was an increase in the fasting plasma C-peptide level, and B-cell stimulation with glucose or glucagon evoked a C-peptide response. Healing of ischaemic damage was reflected in an increase in the C-peptide level. During graft rejection the C-peptide level fell. Measurement of plasma C-peptide levels provides a direct index of the B-cell function of the pancreatic graft. After transplantation the insulin antibody level fell exponentially, with an apparent half life of 10–11 days, whereas the level of total IgG was variable. The results indicate that formation of insulin antibodies ceases immediately on removal of the immunogenic stimulus, that is, on withdrawal of xenogeneic insulin.
Article PDF
Similar content being viewed by others
References
Lillehei RC, Simmons RL, Najarian JS, Weil R, Hisanori V, Ruiz JO, Kjellstrand CM, Goetz FC (1970) Pancreaticoduodenal allotransplantation: Experimental and clinical experience. Ann Surg 172: 405–436
Groth CG, Lundgren G, Arner P, Collste H, Hårdstedt Ch, Lewander R, Östman J (1976) Rejection of isolated pancreatic allografts in patients with diabetes. Surg Gynecol Obstet 143: 933–940
Groth CG, Lundgren G, Gunnarsson R, Amer P, Berg B, Östman J (in press) Segmental pancreatic transplantation with duct ligation or drainage to a jejunal Roux-en-Y loop in nonuremic diabetic patients. Diabetes
Schlichtkrull J, Munck O, Jersild M (1965) The M-value, an index of blood sugar control in diabetics. Acta Med Scand 177: 95–102
Heding LG (1975) Radioimmunological determination of human C-peptide in serum. Diabetologia 11: 541–548
Christiansen AaH (1973) Radioimmunoelectrophoresis in the determination of insulin binding to IgG. Methodological studies. Horm Metab Res 5: 147–154
Ikkos D, Luft R (1957) On the intravenous glucose tolerance test. Acta Endocrinol (Kbh) 25: 312–334
Gliedman ML, Tellis V, Soberman R, Rifkin H, Freed SZ, Veith FJ (1975) The clinical use of steroids in pancreatic transplantation. Transplant Proc 7: 93–98
Horwitz DL, Starr JI, Mako ME, Blackard WG, Rubinstein AH (1975) Proinsulin, insulin, and C-peptide concentrations in human portal and peripheral blood. J Clin Invest 55: 1278–1283
Ludvigsson J, Heding LG, Larsson, Y, Leander E (1977) C-peptide in juvenile diabetics beyond the postinitial remission period. Relation to clinical manifestations at onset of diabetes, remission and diabetic control. Acta Paediatr Scand 66: 177–184
Ludvigsson J, Heding LG (1976) C-peptide in children with juvenile diabetes. A preliminary report. Diabetologia 12: 627–630
Schlichtkrull J, Brande J, Christiansen AaH, Hallund O, Heding LG, Jörgensen KH (1972) Clinical aspects of insulin-anti-genicity. Diabetes 21 (Suppl 2): 649–656
Dixon K, Exon PD, Hughes HR (1972) Insulin antibodies in aetiology of labile diabetes. Lancet I: 343–347
Dixon K, Exon PD, Malins JM (1975) Insulin antibodies and the control of diabetes. Q J Med 176: 543–553
Yue DK, Baxter RC, Turtle JR (1978) C-peptide secretion and insulin antibodies as determinants of stability in diabetes mellitus. Metabolism 27: 35–44
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Östman, J., Arner, P., Groth, C.G. et al. Plasma C-peptide and serum insulin antibodies in diabetic patients receiving pancreatic transplants. Diabetologia 19, 25–30 (1980). https://doi.org/10.1007/BF00258306
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00258306